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To the Editors:
Since the outbreak of the Coronavirus Disease 2019 (COV-
ID-19) pandemic, there has been ongoing debate about the risk 
for immunocompromised patients of developing a severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 
Among them are individuals with myasthenia gravis (MG) 
who often require immunosuppressive therapy, as well as 
symptomatic treatment. Immunosuppression may contribute 
to the treatment of MG exacerbations (e.g. plasmapheresis) or 
constitute a form of maintenance therapy (e.g. steroids or oral 
immunosuppressants) [1]. Due to the possibility of acute res-
piratory failure in the course of both MG and COVID-19, pa-
tients with the coexistence of these conditions may experience 
severe outcomes [2]. So far, it is known that SARS-CoV-2 can 
be transmitted between people via respiratory secretions, 
respiratory droplets and saliva of infected individuals, either 
through direct contact or by using contaminated objects. 
Unfortunately, people can infect others before developing 
disease symptoms. Therefore, the largest clusters of new cases 
are mainly observed within households [3]. 
We present a case report of a 42-year-old woman with 
a diagnosis of generalised myasthenia gravis who was exposed 
to three forms of immunosuppression and to a symptomatic 
infection with SARS-CoV-2 in the other members of her 
three-person household over a short period of time. 
The patient experienced the first symptoms of MG in the 
form of ptosis in 2003. The diagnosis was established in the 
same year by the finding of disturbances of neuromuscular 
transmission in a repetitive nerve stimulation test, the pres-
ence of anti-acetylcholine receptor antibody in the serum, and 
persistent thymus in chest computed tomography. Three years 
later, the patient developed generalised MG. As her symptoms 
had been controlled satisfactorily with pyridostigmine bro-
mide and the short-term oral prednisone therapy was used 
only during the disease exacerbation periods (a therapeutic 
regimen inconsistent with the treatment guidelines for MG), 
she decided not to undergo thymectomy. 
In 2013, azathioprine was added to the treatment regimen 
due to the progression of fatigue and generalised weakness, 
but that drug was discontinued after three months because of 
gastrointestinal adverse events. In 2014, the patient became 
pregnant and used only pyridostigmine bromide. In 2017, 
due to MG exacerbation, steroid therapy was resumed, with 
a partial clinical improvement. Since June 2018, the patient 
has been using pyridostigmine bromide (420 mg/day), pred-
nisone (20 mg/day), and mycophenolate mofetil (MMF)
(1,000 mg/day). 
On 16 February 2020, the patient was admitted to her 
local Neurology Department with a diagnosis of impending 
myasthenic crisis. For this reason, therapeutic cycles of plasma 
exchange were performed, with a total of 7,600 ml of plasma 
replaced, resulting in an improvement from class IVA (severe 
weakness predominantly affecting limb and/or axial muscles) 
to class IIA (mild weakness predominantly affecting limb and/
or axial muscles), according to the clinical classification of 
the Myasthenia Gravis Foundation of America [4]. After the 
patient’s discharge on 24 February, the pre-hospitalisation 
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doses of prednisone and MMF were maintained to avoid 
another MG exacerbation, despite a potential risk of SARS-
CoV-2 infection. 
Unfortunately, on 10 April, the patient’s 45-year-old hus-
band, with a history of arterial hypertension, was diagnosed 
with COVID-19 after a five-day period of runny nose, dry 
cough without shortness of breath, low-grade fever, muscle 
pain, and loss of smell. The following day, the same infection 
was recognised in their five-year-old son, with a history 
of atypical dermatitis, who had been complaining of a dry 
cough, low-grade fever, vomiting and abdominal pain for 
two days. The diagnosis of COVID-19 in both cases was 
established on a basis of symptoms and virus detection in 
nasopharyngeal swabs by the use of real-time reverse-tran-
scription polymerase chain reaction (rRT-PCR). As infected 
persons, the father and the son both underwent two weeks of 
isolation, and treatment with azithromycin for the first five 
days from the diagnosis. After the first week of isolation, 
both infected individuals had completely recovered, and 
three consecutive rRT-PCR tests of their nasopharyngeal 
swabs did not reveal the presence of the virus. During this 
time, despite the use of dual immunosuppressive therapy and 
a six-day period of daily contact with household members 
with the symptomatic SARS-CoV-2 infection, the woman 
was not infected: three rRT-PCR tests of her nasopharyngeal 
swabs were negative. Serum tests performed in the husband 
and son two months later revealed positive titres of IgG and 
IgA antibodies against SARS-CoV-2, with negative IgM titres. 
The woman was seronegative for SARS-CoV-2 in all three 
classes of antibodies analysed, and had not developed any 
symptoms of COVID-19. 
Currently, no conclusive data is available on the risk of 
using immunosuppressive therapies in MG during the COV-
ID-19 pandemic. The international MG/COVID-19 working 
group suggests the maintenance of current treatment and 
recommends that patients on immunosuppressive medications 
should practice extra-vigilant social distancing [2]. Anand et 
al. described the clinical course of COVID-19 in four hospi-
talised MG patients with acetylcholine receptor antibodies and 
concomitant diseases. Three of them were aged over 60 years 
and were using MMF (two at a daily dose of 2,000 mg and 
one at a dose of 1,500 mg) as well as prednisone (5 mg every 
other day, 15 mg every day, and 30 mg every day, respectively) 
before the SARS-CoV-2 infection was confirmed. MMF was 
maintained in all patients on admission, and the mildest course 
of COVID-19 was reported in the subject with the lowest 
baseline dose of this medication. 
However, the authors did not disclose the circumstances 
nor the route of the SARS-CoV-2 infection [5]. Preliminary 
data suggests that the incidence and morbidity rates of COV-
ID-19 in patients on immunosupressive therapies may not 
differ very much from those of the general population [6]. 
Nevertheless, it remains unclear which therapeutic strategy 
should be adopted in an immunosuppressed MG patient 
exposed to close contact with individuals infected with SARS-
CoV-2. Furthermore, the question remains open as to whether 
the risk of SARS-CoV-2 infection is dependent on a dose of 
the immunosuppressive drug, and whether such treatment 
may have a potentially protective effect against this disease. 
It should also be noted that, compared to subjects reported by 
Anand et al., our patient used a lower MMF dose, was younger, 
and had no comorbidities other than MG, which certainly 
reduced her risk of developing the infection [5]. 
The presented case of an immunocompromised MG pa-
tient who was the only member of her three-person household 
not infected with SARS-CoV-2, presents the risk associated 
with immunosuppression in the times of the COVID-19 pan-
demic, a topic which still has not been fully determined. 
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